Study reveals the drug, 5-fluorouracil, acts differently in different types of cancer — a finding that could help researchers design better drug combinations. Since the 1950s, a chemotherapy drug ...
Calcipotriol plus 5-FU immunotherapy activates Th2 immunity, releasing IL-24 cytokines to suppress skin cancer development in patients with actinic keratosis. The combination therapy significantly ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Administration of 5-FU bolus did not affect survival for ...
The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...
Trajectories of premorbid healthcare contact days in veterans with pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...
HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...
Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback